Novavax (LTS:0UP6) Accounts Payable & Accrued Expense : $315 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Novavax Accounts Payable & Accrued Expense?

Novavax's quarterly accounts payable & accrued expense increased from Sep. 2023 ($413 Mil) to Dec. 2023 ($471 Mil) but then declined from Dec. 2023 ($471 Mil) to Mar. 2024 ($315 Mil).

Novavax's annual accounts payable & accrued expense declined from Dec. 2021 ($762 Mil) to Dec. 2022 ($755 Mil) and declined from Dec. 2022 ($755 Mil) to Dec. 2023 ($471 Mil).

Novavax Accounts Payable & Accrued Expense Historical Data

The historical data trend for Novavax's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Accounts Payable & Accrued Expense Chart

Novavax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

15.35

170.97

762.36

755.11

471.33

Novavax Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															643.51	545.64	413.12	471.33	315.09

Novavax Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Novavax (LTS:0UP6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (LTS:0UP6) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

NVAX:USA NVAX:Mexico NVV1:Germany

Address

21 Firstfield Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Novavax (LTS:0UP6) Headlines

No Headlines